(NASDAQ: STRO) Sutro Biopharma's forecast annual revenue growth rate of -1.96% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Sutro Biopharma's revenue in 2025 is $66,434,000.On average, 7 Wall Street analysts forecast STRO's revenue for 2025 to be $5,308,650,174, with the lowest STRO revenue forecast at $3,452,189,372, and the highest STRO revenue forecast at $6,410,617,604. On average, 7 Wall Street analysts forecast STRO's revenue for 2026 to be $4,611,759,452, with the lowest STRO revenue forecast at $1,456,958,546, and the highest STRO revenue forecast at $11,091,466,452.
In 2027, STRO is forecast to generate $5,768,288,923 in revenue, with the lowest revenue forecast at $5,380,188,951 and the highest revenue forecast at $6,483,254,377.